US Patent

US11925704 — Aqueous suspension suitable for oral administration

Method of Use · Assigned to Liqmeds Worldwide Ltd · Expires 2037-06-07 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a liquid oral dosage form of a lipid-lowering agent suitable for oral administration to humans or animals.

USPTO Abstract

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

Drugs covered by this patent

Lipitor (Atorvastatin Calcium) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3853`	—	Lipitor

Patent Metadata

Patent number: US11925704
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Liqmeds Worldwide Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.